Network Pharmacology-Based and Clinically Relevant Prediction of the Potential Targets of Chinese Herbs in Ovarian Cancer Patients

Table 1

Patients’ baseline characteristics and treatments between CHM group and non-CHM group.

		Non-CHM ()	CHM ()	value
Age	<45	16	21	0.154
	45-59	76	53
	≥60	23	13
Tumor location	Left	13	18	0.102
	Right	41	22
	Bilateral	61	47
Pathological pattern	Endometrioid adenocarcinoma	31	15	0.263
	Serous adenocarcinoma	74	63
	Other types	10	9
FIGO stage	Stage I	7	3	0.365
	Stage II	25	12
	Stage III	68	58
	Stage IV	15	14
CA-125 (kU/L)	<35	3	2	0.971
	35-280	21	15
	>280	91	70
Chemotherapy method	Intravenous injection	99	72	0.516
	Intravenous injection+intraperitoneal perfusion	16	15
Radiotherapy	Yes	6	8	0.270
	No	109	79
Biotherapy	Yes	24	28	0.069
	No	91	59
Targeted therapy	Yes	6	4	0.841
	No	109	83